Prescription medicine
Hydrocortisone and pramoxine Brand names: Pramosone, Analpram, Epifoam, Proctofoam
Hydrocortisone and pramoxine (Analpram) is a prescription medicine. FDA's NDC Directory lists it from 5 generic labelers, and pharmacies paid $2.89 per gram (Hydrocort-pramoxine 1%-1% cream) in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the hydrocortisone and pramoxine FDA label on DailyMed (effective June 30, 2025, Legacy Pharma USA Inc.); every hydrocortisone and pramoxine label on DailyMed.
Highlights of the record
FDA label of June 30, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageTopical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Forms and strengths
- 1 g/100g / 1 g/100g
- 10 mg/g / 10 mg/g
- 10 mg/ml / 10 mg/ml
- 25 mg/ml / 10 mg/ml
- 25 mg/g / 10 mg/g
- 100 mg/10g / 100 mg/10g
Cream; lotion; aerosol (foam).
On the market
- Generic approvals
- 8 first November 13, 1973; 6 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 5 of which 5 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $2.89 per gram Hydrocort-pramoxine 1%-1% cream
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 2 since 2021 0 Class I among all firms' recalls; latest January 21, 2022
- FAERS reports
- 1,001 through July 30, 2026
What is hydrocortisone and pramoxine used for?
From the label: indications and usageTopical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
FDA pharmacologic class: Corticosteroid.
Source: FDA drug label (Pramosone Cream), Legacy Pharma USA Inc., effective June 30, 2025 (SPL set 6a9fb75b-a2f7-4eca-8dce-d7eb5c122476), via openFDA; the full label on DailyMed
Is there a generic for hydrocortisone and pramoxine (Analpram)?
The FDA approved the first generic hydrocortisone and pramoxine on November 13, 1973. 8 generic applications are approved; 6 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists hydrocortisone and pramoxine from 5 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for hydrocortisone and pramoxine (Analpram)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $2.89 per gram (Hydrocort-pramoxine 1%-1% cream), down 16% from $3.45 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Hydrocort-pramoxine 2.5-1% cream (generic)
- Epifoam foam (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Analpram hc 1% cream | Generic | $2.89 per gram | n/a | n/a |
| Hydrocort-pramoxine 1%-1% cream | Generic | $2.89 per gram | n/a | -16% |
| Hydrocort-pramoxine 2.5-1% cream | Generic | $1.59 per gram | n/a | -12% |
| Epifoam foam | Brand | $10.00 per gram | n/a | +5% |
| Proctofoam-hc 1%-1% foam | Brand | $19.38 per gram | n/a | +5% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has hydrocortisone and pramoxine been recalled?
The FDA's Enforcement Report lists 2 recalls naming hydrocortisone and pramoxine since 2021: 0 Class I (the most serious), 2 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| January 21, 2022 | Class II | Mylan Pharmaceuticals Inc | cGMP deficiencies |
| March 15, 2021 | Class II | Cardinal Health Inc. | CGMP Deviations: Intermittent exposure to temperature excursion during storage. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What do FAERS reports show for hydrocortisone and pramoxine?
The FDA Adverse Event Reporting System holds 1,001 reports that list hydrocortisone and pramoxine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 48 are coded as a death and 213 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other corticosteroids
- the pharmacologic class, with prices and generics
- Hydrocortisone and pramoxine side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other